| Molecule Name |
DB01612
|
| DrugBank Groups |
Approved
|
| Cluster No |
803
|
| Smiles |
O=NOCCCCC
|
| Download |
mol2, pdbqt
|
| TPSA |
38,66
|
| Non-H Atoms |
8
|
| Non-C/H Atoms |
3
|
| Metal-Atoms |
0
|
| Electronegative Atoms |
3
|
| Stereo Centers |
0
|
| Rotatable Bonds |
5
|
| Rings Closures |
0
|
| Small Rings |
0
|
| Aromatic Rings |
0
|
| Aromatic Atoms |
0
|
| sp3-Atoms |
6
|
| Symmetric atoms |
0
|
| cLogS |
-1,467
|
| MW |
117,147
|
| cLogP |
2,3114
|
| HBA |
3
|
| HBD |
0
|
| Ro5 violations |
0
|
| Druglikeness |
-9,5397
|
| DrugScore |
0,170950521748009
|
| Mutagenic |
high
|
| Tumorigenic |
high
|
| Reproductive Effective |
none
|
| Irritant |
none
|
| Blood-Brain Barrier |
BBB+
|
| Human Intestinal Absorption |
HIA+
|
| Caco-2 Permeability |
Caco2+
|
| P-glycoprotein Substrate |
Non-substrate
|
| P-glycoprotein Inhibitor |
Non-inhibitor
|
| P-glycoprotein Inhibitor 2 |
Non-inhibitor
|
| Renal Organic Cation Transporter |
Non-inhibitor
|
| Aqueous solubility |
-1,7366
|
| Caco-2 Permeability 2 |
1,1358
|
| Subcellular localization |
Mitochondria
|
| CYP450 2C9 Substrate |
Non-substrate
|
| CYP450 2D6 Substrate |
Non-substrate
|
| CYP450 3A4 Substrate |
Non-substrate
|
| CYP450 1A2 Inhibitor |
Non-inhibitor
|
| CYP450 2C9 Inhibitor |
Non-inhibitor
|
| CYP450 2D6 Inhibitor |
Non-inhibitor
|
| CYP450 2C19 Inhibitor |
Non-inhibitor
|
| CYP450 3A4 Inhibitor |
Non-inhibitor
|
| CYP Inhibitory Promiscuity |
Low CYP Inhibitory Promiscuity
|
| Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
| Human Ether-a-go-go-Related Gene Inhibition 2 |
Non-inhibitor
|
| AMES Toxicity |
AMES toxic
|
| Carcinogens |
Carcinogens
|
| Fish Toxicity |
Low FHMT
|
| Fish Toxicity (pLC50, mg/L) |
1,7831
|
| Tetrahymena Pyriformis Toxicity |
Low TPT
|
| Tetrahymena Pyriformis Toxicity (pIGC50, ug/L) |
-0,4962
|
| Honey Bee Toxicity |
High HBT
|
| Biodegradation |
Ready biodegradable
|
| Acute Oral Toxicity |
II
|
| Rat Acute Toxicity (LD50, mol/kg) |
2,829
|
| Carcinogenicity (Three-class) |
Non-required
|
